All News Results

  • Global Stocks Waver Amid Uncertainty on Rates, Trade Talks

    Global stocks paused on Tuesday as investors took a wait-and-see approach to trade developments and the Federal Reserve's next policy moves. The Stoxx Europe 600 ticked up 0.2%, with rises in its health care constituents mostly offset by losses in its basic resources sector. Shares in the world's largest miner, BHP Group PLC, dropped 1.2% despite posting a record payout off the back of strong profits, after Chief Executive Andrew Mackenzie said the trade dispute between the...

  • Britain's Johnson opening Brexit bid: rip out the Irish border backstop

    • BY Reuters|
    • 04:21 AM ET 08/20/2019

    Prime Minister Boris Johnson has fired the opening salvo in his bid to renegotiate Britain's divorce from the European Union, demanding that an insurance policy for the Irish border be removed from the Brexit deal and replaced with a pledge.

  • FOREX-Euro weakens vs dollar as Treasury yields pick up on stimulus talks

    * Chinese yuan matched earlier a six-day low vs dollar. * Pound weaker against the euro, stable vs dollar. * Graphic: World FX rates in 2019 http://tmsnrt.rs/2egbfVh. By Olga Cotaga.

  • European shares gain for third straight session, AstraZeneca boosts

    • BY Reuters|
    • 04:15 AM ET 08/20/2019

    * Gains in AstraZeneca (AZN) lift FTSE 100. * Pandora tops STOXX 600 after keeping FY forecast. * Banks, miners keep gains in check. By Shreyashi Sanyal and Amy Caren Daniel. European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca (AZN) gained on positive data from a late-stage study.

  • Greek current account surplus widens in June, tourism revenues rise

    Greece's current account balance showed a larger surplus in June compared to the same month last year, on the back of a smaller trade gap and a stronger services surplus, the Bank of Greece ...

  • Europe stocks advance for third session in a row

    Europe stocks on Tuesday rose for a third session in a row, supported by murmurings that fiscal policy could join monetary action in supporting the global economy. The Stoxx Europe 600 rose 0.3% to 374.88, led by drugmakers including AstraZeneca, which reported a favorable study, and household product firms including Unilever. The German DAX rose 0.2% to 11735.18, the French CAC 40 gained 0.2% to 5383.04 and the U.K.

  • China Shanghai Rubber Futures Closing Prices, Volume

    Tuesday, August 20 2019 Natural Rubber Turnover: 243,028 lots Open High Low Settle Prev. Change Vol Open Settle Interest Sep-19 10,560 10,570 10,480 10,515 10,495 20 23,320 131,082 Oct-19 10,630 10,640 10,560 10,575 10,580 -5 54 128 Nov-19 10,670 10,685 10,610 10,645 10,610 35 1,346 12,956 Jan-20 11,615 11,670 11,535 11,590 11,550 40 207,906 302,352 Mar-20--- 11,725 11,725 0 0 28 Apr-20 11,895 11,895 11,855 11,875 11,755 120 4 80 May-20 11,785 11,840 11,740 11,780 11,755 25...

  • European shares rise for third straight session

    • BY Reuters|
    • 03:23 AM ET 08/20/2019

    European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca (AZN) surged on results of a late-stage study. Shares of the drugmaker rose 1.5% after the company said its diabetes drug Farxiga met the main goal of the study for the treatment of patients with heart failure.

  • Euro zone rates edge lower amid ongoing easing expectations

    * Euro zone periphery govt bond yields http://tmsnrt.rs/2ii2Bqr. Euro zone rates edged lower on Tuesday as markets continued to focus on the prospect of fiscal stimulus in Germany and verbal easing from ECB policymaker Olli Rehn.

  • Russia accuses U.S. of stoking tensions with missile test: TASS

    • BY Reuters|
    • 03:02 AM ET 08/20/2019

    Russia accused the United States on Tuesday of stoking military tensions by testing a ground-launched cruise missile, but said it would not be drawn into an arms race, TASS news agency reported.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.